Pro-Pharmaceuticals gets compassionate use for Davanat/5-FU to treat patient with bile duct cancer

By E. Janene Geiss

Philadelphia, Feb. 2 - Pro-Pharmaceuticals, Inc. announced Thursday that the Food and Drug Administration has approved a request for a "compassionate use" Investigational New Drug application for the use of Davanat/5-FU to treat another patient who has cholangiocarcinoma, or cancer of the bile duct.

Davanat is a proprietary polysaccharide in a Carbosome formation that target delivers chemotherapy drugs to receptors (lectins) found on cancer cells, according to a company news release.

Pro-Pharmaceuticals is a Newton, Mass., pharmaceutical company developing proprietary carbohydrate-based compounds to enhance the treatment of serious diseases with a focus on increasing the efficacy and decreasing the toxicity of approved chemotherapy drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.